Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors

Table 3

Prevalence of abnormal glucose metabolism, lipid metabolism, and metabolic syndrome features in HIV-infected adolescents receiving protease inhibitor- (PI-) based highly active antiretroviral therapy (HAART).

Diagnosis	(%)
Abnormal glucose metabolism	34 (42.5)
(i) Prediabetes	17 (22.1)
IGT	15 (19.5)
IFG	2 (2.6)
(ii) Diabetes	3 (3.8)
(iii) Insulin resistance	27 (33.8)
Abnormal lipid metabolism	56 (70.0)
(i) Hypertriglyceridemia	35 (43.8)
(ii) High LDL-cholesterol	17 (21.3)
(iii) Low HDL-cholesterol	31 (38.8)
High blood pressure	7 (8.8)
Metabolic syndrome	8 (10.0)
(i) Obesity plus 2 metabolic syndrome features	6 (7.5)
(ii) Obesity plus 3 metabolic syndrome features	2 (2.5)
Metabolic syndrome features without obesity	16 (20.0)
(i) 2 metabolic syndrome features	14 (17.5)
(ii) 3 metabolic syndrome features	2 (2.5)

IGT, impaired glucose tolerance; IFG, impaired fasting glucose.